Rungtivasuwan Kanokrat, Avihingsanon Anchalee, Thammajaruk Narukjaporn, Mitruk Siwaporn, Burger David M, Ruxrungtham Kiat, Punyawudho Baralee, Pengsuparp Thitima
Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Antimicrob Agents Chemother. 2015;59(6):3240-5. doi: 10.1128/AAC.04930-14. Epub 2015 Mar 23.
Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively. Genetic polymorphisms of these transporters may affect the plasma concentrations of tenofovir. Therefore, the aim of this study was to investigate the influence of genetic and nongenetic factors on tenofovir plasma concentrations. A cross-sectional study was performed in Thai HIV-infected patients aged ≥18 years who had been receiving tenofovir disoproxil fumarate at 300 mg once daily for at least 6 months. A middose tenofovir plasma concentration was obtained. Multivariate analysis was performed to investigate whether there was an association between tenofovir plasma concentrations and demographic data, including age, sex, body weight, estimated glomerular filtration rate (eGFR), hepatitis B virus coinfection, hepatitis C virus coinfection, duration of tenofovir treatment, concomitant use of ritonavir-boosted protease inhibitors, and polymorphisms of ABCC2 and ABCC4. A total of 150 Thai HIV-infected patients were included. The mean age of the patients was 43.9 ± 7.2 years. The mean tenofovir plasma concentration was 100.3 ± 52.7 ng/ml. In multivariate analysis, a low body weight, a low eGFR, the concomitant use of ritonavir-boosted protease inhibitors, and the ABCC4 4131T → G variation (genotype TG or GG) were independently associated with higher tenofovir plasma concentrations. After adjusting for weight, eGFR, and the concomitant use of ritonavir-boosted protease inhibitors, a 30% increase in the mean tenofovir plasma concentration was observed in patients having the ABCC4 4131 TG or GG genotype. Both genetic and nongenetic factors affect tenofovir plasma concentrations. These factors should be considered when adjusting tenofovir dosage regimens to ensure the efficacy and safety of a drug. (This study has been registered at ClinicalTrials.gov under registration no. NCT01138241.).
替诺福韦(TFV)通过肾脏排泄消除,这一过程由分别由ABCC2和ABCC4编码的多药耐药蛋白2(MRP2)和MRP4介导。这些转运蛋白的基因多态性可能会影响替诺福韦的血浆浓度。因此,本研究的目的是调查遗传和非遗传因素对替诺福韦血浆浓度的影响。对年龄≥18岁、每天一次接受300mg富马酸替诺福韦二吡呋酯治疗至少6个月的泰国HIV感染患者进行了一项横断面研究。获取了替诺福韦的中剂量血浆浓度。进行多变量分析以调查替诺福韦血浆浓度与人口统计学数据之间是否存在关联,这些数据包括年龄、性别、体重、估计肾小球滤过率(eGFR)、乙型肝炎病毒合并感染、丙型肝炎病毒合并感染、替诺福韦治疗持续时间、利托那韦增强型蛋白酶抑制剂的联合使用以及ABCC2和ABCC4的多态性。共纳入了150名泰国HIV感染患者。患者的平均年龄为43.9±7.2岁。替诺福韦的平均血浆浓度为100.3±52.7ng/ml。在多变量分析中,低体重、低eGFR、利托那韦增强型蛋白酶抑制剂的联合使用以及ABCC4 4131T→G变异(基因型TG或GG)与较高的替诺福韦血浆浓度独立相关。在调整体重、eGFR和利托那韦增强型蛋白酶抑制剂的联合使用后,观察到ABCC4 4131 TG或GG基因型患者的替诺福韦平均血浆浓度增加了30%。遗传和非遗传因素均会影响替诺福韦的血浆浓度。在调整替诺福韦给药方案时应考虑这些因素,以确保药物的疗效和安全性。(本研究已在ClinicalTrials.gov注册,注册号为NCT01138241。)